Navigation Links
European Patent Office Upholds GlideScope® Video Laryngoscope Patent
Date:8/20/2010

BOTHELL, Wash., Aug. 20 /PRNewswire/ -- The European Patent Office ("EPO") Board of Appeals has issued a formal written decision to uphold European Patent No. EP 1307131 for Verathon Inc.'s GlideScope video laryngoscopes.

(Logo: http://photos.prnewswire.com/prnh/20061011/SFW044LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20061011/SFW044LOGO)

The ruling, issued on July 26th, keeps the GlideScope patent in force in several European countries, including the UK, Germany, France, Denmark, Ireland and Italy. The patent, which does not expire until 2021, also remains valid in several countries outside of Europe.

The GlideScope patent, originally granted in Europe in May 2005, was opposed by Aircraft Medical Limited at the European Patent Office in February 2006. Aircraft Medical, maker of the McGrath video laryngoscope, is based in Edinburgh, Scotland.

Verathon® prevailed at a hearing in October 2007, when the EPO's Opposition Division rejected Aircraft Medical's opposition and upheld the GlideScope patent with amended claims.

The EPO's formal written decision in July concludes the Appeal filed by Aircraft Medical against Verathon's patent and the previous decision by the Opposition Division upholding the GlideScope patent.

About GlideScope

GlideScope video laryngoscopes provide a consistently clear, real-time view of the airway and of endotracheal tube placement. Designed for "1st Pass Success," GlideScope instruments, which minimize the need for "blind" intubation procedures, come in both single use and reusable configurations, and in a variety of sizes for patients from preterm to morbidly obese.

About Verathon Inc.

Verathon designs and manufactures reliable, state-of-the-art medical devices and services that offer a meaningful improvement in patient care to the health care community. The company's noninvasive BladderScan® instrument is a standard of care for portable bladder volume measurement. The brand is found in over 60 countries in Urology and Primary Care practices, as well as Acute and Extended Care facilities. With the January 2006 acquisition of Saturn Biomedical Systems in Vancouver, Canada, Verathon entered Anesthesiology, Critical Care and Emergency markets with the GlideScope Video Laryngoscope (GVL®) brand. Verathon is headquartered in Bothell, Washington and operates as a subsidiary of Roper Industries. For more information, please visit www.verathon.com.

Media Contact:

Jane Mueller, VP of Marketing, 425.867.1348, Ext. 5600

Copyright 2010, Verathon Inc. GlideScope, GVL, BladderScan, their respective symbols, Verathon and the Verathon torch symbol are registered trademarks of Verathon Inc.


'/>"/>
SOURCE Verathon Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
2. Cardiac Dimensions® Announces Presentation of 12-Month Follow-up Data of TITAN™ Trial at European Society of Cardiology Meeting
3. Reportlinker Adds European Markets for Small Joint Reconstructive Devices 2010 (15 Countries)
4. PDL BioPharma Receives Letter from Genentech Relating to European Patents
5. Western European Market for Image-guided and Robot-assisted Surgery
6. European Research Project Aims to Improve the Diagnosis and Therapy of Brain Diseases
7. Health Robotics CytoCare Continues European Expansion With Grifols and Vall dHebron University Hospital
8. Reportlinker Adds European Market for Ventilation and Airway Management Devices
9. Reportlinker Adds Western European Disinfectant Gels and Scrubs Market
10. Sanofi-Aventis and Novalar File Marketing Authorization Application for OraVerse® in Five Key European Countries
11. Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... IBM ) Research has today announced new research developments ... retina. The Melbourne based IBM researchers ... in retina images, which could in the future offer doctors ... who may be at risk of eye diseases – such ... world. The research began in 2015 and ...
(Date:2/21/2017)... , Feb. 21, 2017 Diabetic Shoes Market: Overview ... ... be described as a disease, which is marked by high ... and insulin action. The disease has become a global epidemic ... Diabetes affects several organs of the body including eyes, kidneys, ...
(Date:2/21/2017)... -- /PR Newswire/ -- UBM Medica,s Eye Care Group ( ... Modern Retina ( www.modernretina.com ), a new ... Built upon the success of Ophthalmology Times , ... in the areas of retinal surgery, clinical information, research, ... informational needs and filling existing educational gaps, Modern ...
Breaking Medicine Technology:
(Date:2/20/2017)... BROOK, Ill. (PRWEB) , ... February 20, 2017 ... ... potential to reduce the rate at which women are called back for additional ... the journal Radiology . , In 2011, the U.S. Food and Drug ...
(Date:2/20/2017)... ... 20, 2017 , ... Daily Body Restore, "DBR" a company ... “good” bacteria in the body, announced its Daily Body Restore® supplement is now ... Body Restore® is made with a unique combination of digestive enzymes and probiotics ...
(Date:2/20/2017)... ... February 20, 2017 , ... For Immediate Release, ... a leading provider of innovative software for connected home healthcare, today announced ... care journey management for home healthcare. , Built on Orbita Health ...
(Date:2/20/2017)... Yardley, PA (PRWEB) , ... February 20, 2017 , ... ... are collaborating to help health care providers better manage patient health risks, foster behavior ... largest medication video library in the world, will present a demonstration of its video ...
(Date:2/20/2017)... ... February 20, 2017 , ... Best Doctors® and IBM ... benefit for companies that want to help members of their workforce battling cancer. ... access to Watson’s suite of oncology offerings for insights on cancer treatment options, ...
Breaking Medicine News(10 mins):